Core Points - The company held its 7th meeting of the 2nd Supervisory Board on August 18, 2025, where all members confirmed the accuracy and completeness of the information disclosed [1] - The Supervisory Board approved the 2025 Half-Year Report and its summary, affirming that the report reflects the company's actual situation without any misleading statements [2] - The Board also approved the postponement of fundraising projects and the use of excess funds for ongoing projects, stating that this will not adversely affect the company's operations and aligns with regulatory requirements [2] - The use of raised funds to replace self-raised funds previously invested in projects was also approved, amounting to 428.1851 million yuan, which includes 412.6070 million yuan for projects and 15.5781 million yuan for issuance costs [3] - The company plans to use its own funds for part of the project payments and will replace them with raised funds later, ensuring compliance with regulations and protecting shareholder interests [3][5]

Core Viewpoint - The company has announced a delay in its fundraising project and plans to use the excess funds raised from its initial public offering (IPO) for ongoing projects, specifically the "Hankao Smart Home Hardware Automation Manufacturing Base" [1][5][9]. Fundraising Overview - The company successfully raised a total of approximately RMB 617.35 million by issuing 40.01 million shares at a price of RMB 15.43 per share, with all funds received by July 25, 2025 [1][2]. - The total amount of excess funds (including interest) is approximately RMB 90.62 million, which will be allocated to the ongoing project [1][6]. Project Delay Details - The company has decided to adjust the timeline for the fundraising projects to reach their intended usable state, now set for December 2026, while maintaining the project scope and funding usage [5][9]. - The delay is attributed to longer installation and debugging periods for automated production lines, fluctuations in industry trends, and changing market demands [5][10]. Use of Excess Funds - The excess funds will be specifically directed towards the "Hankao Smart Home Hardware Automation Manufacturing Base" project, increasing the total investment in this project to approximately RMB 460.62 million [6][7]. - The project aims to enhance the company's research and design capabilities, improve automation in production, and expand existing production capacity [6][8]. Project Investment Justification - The project is deemed necessary to meet the growing market demand and to enhance production efficiency, as the current production lines are nearing full capacity [7][8]. - The project is expected to yield a post-tax internal rate of return of 20.07% and a payback period of approximately 6.94 years [8]. Approval Process - The board of directors and the supervisory board have approved the project delay and the use of excess funds, confirming that these changes will not adversely affect the company's operations or shareholder interests [9][10].

Core Viewpoint - The report details the fundraising and usage status of Shenzhen Panhai Tonglian Precision Manufacturing Co., Ltd. as of June 30, 2025, highlighting the total amount raised, the allocation of funds, and compliance with regulatory requirements [2][4][5]. Fundraising Overview - The company raised a total of RMB 855.2 million by issuing 20 million shares at RMB 42.76 per share, with a net amount of RMB 772.85 million after deducting fees [2][3]. - The funds were received on December 22, 2021, and have been audited by Tianzhi International Accounting Firm [3]. Fund Usage and Balance - As of June 30, 2025, the company has utilized RMB 560.27 million of the raised funds, leaving a balance of RMB 105.13 million in the special account [3][5]. - The funds were allocated to various projects, including RMB 349.64 million for the MIM product production base and RMB 59.77 million for the R&D center [6][8]. Fund Management - The company has established a management system for the raised funds, ensuring they are stored in dedicated accounts and used according to regulatory guidelines [4][5]. - A tripartite supervision agreement was signed with banks to ensure proper management of the funds [4]. Project Status and Adjustments - The company has not made any changes to the investment projects as of the reporting date, but adjustments to the investment amounts and internal structures for specific projects have been proposed [7][8]. - The completion dates for the MIM product production base and R&D center projects have been extended to December 31, 2025, due to phased equipment procurement [8][9]. Compliance and Reporting - The company asserts that it has complied with all relevant regulations regarding the management and disclosure of the raised funds, with no violations reported [7][9].

Fundraising Overview - The company raised a total of RMB 3,499,999,996.64 by issuing 597,269,624 shares at RMB 5.86 per share, with a net amount of RMB 3,476,933,798.91 after deducting issuance costs [1][2] - As of June 30, 2025, the remaining balance of the raised funds was RMB 2,892,733,673.75 after utilizing RMB 584,842,678.10 for investment projects [1][2] Fund Management - The company has established a fundraising management system in compliance with relevant regulations to ensure proper use and oversight of the funds [1][2] - Specific bank accounts for fundraising have been set up, and agreements with banks and sponsors have been signed to ensure fund security [1][2] Fund Utilization - As of June 30, 2025, the company has utilized RMB 161,636,430.00 of self-raised funds for investment projects, with RMB 58,500,000.00 being replaced by the raised funds [2][3] - The company has not used idle funds for temporary working capital and has engaged in cash management to enhance fund efficiency, generating RMB 278,000.00 in interest income [2][3] Project Investment Status - The company has not changed the intended use of the raised funds and has reported no significant issues in fund management or disclosures [2][3] - The investment projects are progressing, with specific projects achieving varying levels of completion, such as the construction of a semi-submersible vessel reaching 99.57% completion [3][4]

Core Viewpoint - The company has established a fundraising management system to regulate the use and management of raised funds, ensuring transparency and protecting investor interests [2][3]. Group 1: Fundraising Management Principles - The company defines fundraising as funds raised through stock issuance for specific purposes, excluding funds for equity incentive plans [2]. - The management system serves as a basic guideline for the use and management of raised funds, ensuring compliance by subsidiaries involved in fundraising projects [3]. - The company must ensure that raised funds are used only for publicly disclosed projects, with any changes requiring shareholder approval and proper disclosure [3][4]. Group 2: Fund Storage and Supervision - Upon receiving funds, the company must promptly complete verification procedures and store the funds in a designated account [4]. - A specialized account management system is implemented to enhance oversight of fund usage [4][5]. - The company must establish a tripartite supervision agreement with the sponsoring institution and the bank holding the funds, detailing the management and withdrawal conditions [5][6]. Group 3: Fund Usage Regulations - Funds must be used strictly according to the investment plan disclosed in the issuance application, and any significant deviations must be announced [6][12]. - The company is prohibited from using raised funds for high-risk investments or for providing financial assistance to others [12][13]. - Any temporary use of idle funds for cash management must be disclosed, including the reasons for idleness and the measures taken to ensure project continuity [8][9]. Group 4: Handling of Surplus Funds - Surplus funds should be used for ongoing or new projects, with a clear plan submitted for approval [10][11]. - The company must disclose the necessity and rationale for using surplus funds for cash management or temporary liquidity support [10][11]. - If surplus funds are to be permanently reallocated, the company must follow the appropriate approval and disclosure procedures [17][18]. Group 5: Project Changes and Reporting - Any changes to fundraising projects must be approved by the board and disclosed, including reasons and implications [13][14]. - The company must continuously monitor project progress and report any significant deviations from the investment plan [18][19]. - Annual reports must include a detailed account of the management and usage of raised funds, along with any necessary adjustments to the investment plan [18][19].

Core Viewpoint - The company plans to use its own funds to pay for investment projects and will replace these funds with raised capital in an equivalent amount, which is aimed at optimizing the payment method for investment projects and improving the efficiency of fund usage [1][10]. Fundraising Overview - The company raised a total of RMB 814,655,556 through a private placement of 164,576,880 shares at a price of RMB 4.95 per share, with a net amount received of RMB 797,000,565.02 after deducting issuance costs [1]. - As of October 29, 2021, the company had replaced RMB 22,866,773.28 of its own funds with raised capital for investment projects and issuance costs [2]. Fund Management - The company has established a management method for the use of raised funds to ensure compliance with relevant laws and regulations, and has opened dedicated accounts for raised funds at several banks [2][3]. - The company has signed a tripartite supervision agreement with banks and the sponsor to manage the raised funds [3]. Investment Project Status - As of June 30, 2025, the actual use of raised funds for investment projects was RMB 80,537,770, which is 47.42% of the originally planned amount [7]. - The company has adjusted its investment plans, reallocating funds from the "Special Sewing Equipment and Intelligent Workstation Technology Renovation Project" to the "Investment in Acquiring 80% Equity of Shanghai Feier Automotive Parts Co., Ltd." [7][8]. Use of Own Funds - The company intends to use its own funds for certain overseas project expenditures that require foreign currency payments, with plans to replace these funds with raised capital within six months [9]. - The process for replacing funds involves a series of approvals and monthly summaries of expenditures made with the company's own funds [9]. Impact on the Company - The use of self-funds for investment projects is expected to enhance fund management efficiency, reduce financial costs, and not affect the company's normal operations or the implementation of investment projects [10]. Approval Process - The board of directors and supervisory board approved the use of self-funds for investment projects on August 27, 2025, without needing to submit the matter to the shareholders' meeting [10]. Sponsor's Verification Opinion - The sponsor has verified that the company's use of self-funds for investment projects and subsequent replacement with raised funds has followed necessary procedures and does not harm the interests of the company or its shareholders [11].

Group 1 - The board of directors of Shanghai Xinzhi Software Co., Ltd. held its 23rd meeting on August 29, 2025, with all 7 directors present, confirming the legality and validity of the meeting [1] - The board approved the 2025 semi-annual report, which objectively reflects the company's operational and financial status, adhering to relevant regulations [2][4] - The board also approved the special report on the storage and use of raised funds for the first half of 2025, confirming that the funds were stored in dedicated accounts and used appropriately [2][3] - A semi-annual evaluation report on the company's quality improvement and efficiency enhancement action plan for 2025 was also approved, with unanimous support from the board [4]

Core Points - The company held its 15th meeting of the 10th Board of Directors via telecommunication, with all 9 directors present, and confirmed compliance with legal and regulatory requirements [1] - The board approved the report on asset impairment provision and asset write-off for the first half of 2025, totaling a write-off of 2,088,101.13 yuan for bad debt provisions [2] - The board also approved the half-year report for 2025, which will be disclosed on August 30, 2025, after being reviewed by the audit committee [2] - A special report on the use of raised funds for the first half of 2025 was approved, with unanimous support from the board [2] - The board reviewed a risk assessment report regarding Shanghai Electric Group Financial Co., Ltd., with certain directors abstaining from voting due to conflicts of interest [3] - The board approved an increase in the amount of daily related party transactions for 2025, with independent directors reviewing the proposal [3] - The board approved amendments to the company's governance system to align with the latest regulatory requirements and improve operational standards [4][5]

Core Viewpoint - The report provides a comprehensive overview of the fundraising activities and usage of funds by Liaoning Chengda Biological Co., Ltd. for the first half of 2025, highlighting the total amount raised, the allocation of funds, and the management of surplus funds [1][2][3]. Fundraising Overview - The total amount raised from the initial public offering (IPO) was RMB 4,581,500,000, with all funds received by October 25, 2021 [1]. - As of June 30, 2025, the balance in the fundraising account was RMB 434,929,298.11, after utilizing RMB 1,423,828,419.14 for various projects [1][2]. Fund Usage and Management - The company has invested a total of RMB 783,049,371.27 from the raised funds, with specific allocations for projects such as the human vaccine construction project and the biological product research and development base [1][3]. - The company has established a fundraising management system to ensure the proper use and efficiency of the funds, adhering to relevant laws and regulations [1][3]. Project Investment and Adjustments - The company has made adjustments to its fundraising projects, including the completion of the human vaccine construction project and the initiation of cash management for idle funds, allowing for investment in safe financial products [3][4]. - A total of RMB 69,000,000 from over-raised funds was permanently allocated to supplement working capital [4][5]. Financial Management Practices - The company has not used idle funds for temporary working capital supplementation during the reporting period, ensuring that all funds are allocated according to the planned projects [3][4]. - The company has also engaged in cash management practices, allowing for the investment of up to RMB 1.6 billion in safe financial products, with a focus on maintaining liquidity and security [3][4]. Compliance and Reporting - The company has complied with all relevant regulations regarding the use and disclosure of fundraising activities, ensuring transparency and accountability in its financial practices [4][5]. - No violations of fundraising usage and management regulations were reported during the period [4][5].

Fundraising Overview - The company raised a total of RMB 600 million through the issuance of 6 million convertible bonds at a face value of RMB 100 each, with the funds fully received by August 17, 2023 [1] - After deducting issuance costs of RMB 11,249,651.93, the net amount raised was RMB 588,750,348.07 [1] - As of June 30, 2025, the company had utilized RMB 591,208,771.55 of the raised funds, leaving a balance of RMB 1,010,405.54 [1][4] Fund Management - The company has established a management system for the raised funds, ensuring they are stored in dedicated accounts to safeguard investor interests [1] - The funds are held in special accounts at China Minsheng Bank, CITIC Bank, and Industrial Bank, with regulatory agreements in place to ensure proper oversight [1] Fund Utilization - The company has not made any changes to the implementation locations or methods for the fundraising projects during the reporting period [2] - A total of RMB 73,540,370.58 has been approved for replacement of pre-invested funds and issuance costs, which has been completed as of June 30, 2025 [2] - There are no instances of idle funds being temporarily used to supplement working capital, nor are there any surplus funds or over-raised funds being utilized [3][4] Project Status - As of June 30, 2025, the precision optical lens production project has reached a state of readiness for use, although no benefits have been realized yet [3] - The company has confirmed that there are no significant changes in the feasibility of the fundraising projects [3]